State Street Corp Revance Therapeutics, Inc. Transaction History

State Street Corp

$2.25 Trillion
Q2 2024

A detailed history of State Street Corp transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 2,283,640 shares of RVNC stock, worth $5.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,283,640

Previous 2,358,777 3.19%

Holding current value

$5.87 Million

Previous $11.6 Million 49.44%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.34 - $4.73 $175,820 - $355,398	-75,137 Reduced 3.19%	2,283,640 $5.87 Million
Q1 2024 May 15, 2024	SELL	$4.65 - $9.31 $757,559 - $1.52 Million	-162,916 Reduced 6.46%	2,358,777 $11.6 Million
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $1.1 Million - $2.11 Million	188,585 Added 8.08%	2,521,693 $22.2 Million
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $3.24 Million - $7.08 Million	282,326 Added 13.77%	2,333,108 $26.8 Million
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $2.54 Million - $3.87 Million	103,019 Added 5.29%	2,050,782 $51.9 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $1.87 Million - $3.59 Million	-101,832 Reduced 4.97%	1,947,763 $62.7 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $7.94 Million - $13.3 Million	433,142 Added 26.8%	2,049,595 $37.8 Million
Q3 2022 Nov 15, 2022	SELL	$14.33 - $28.47 $2.34 Million - $4.65 Million	-163,340 Reduced 9.18%	1,616,453 $43.6 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $2.75 Million - $4.86 Million	238,356 Added 15.46%	1,779,793 $24.6 Million
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $314,055 - $516,056	-25,409 Reduced 1.62%	1,541,437 $30.1 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $735,239 - $1.64 Million	59,008 Added 3.91%	1,566,846 $25.6 Million
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $1.84 Million - $2.37 Million	71,394 Added 4.97%	1,507,838 $42 Million
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $2.29 Million - $2.72 Million	85,278 Added 6.31%	1,436,444 $42.6 Million
Q1 2021 May 17, 2021	SELL	$24.03 - $29.97 $2.86 Million - $3.57 Million	-119,110 Reduced 8.1%	1,351,166 $37.8 Million
Q4 2020 Feb 16, 2021	BUY	$23.41 - $28.34 $3.04 Million - $3.68 Million	129,870 Added 9.69%	1,470,276 $41.7 Million
Q3 2020 Nov 10, 2020	SELL	$23.23 - $34.3 $224,727 - $331,818	-9,674 Reduced 0.72%	1,340,406 $33.7 Million
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $2.41 Million - $5.07 Million	191,025 Added 16.48%	1,350,080 $33 Million
Q1 2020 May 11, 2020	BUY	$12.46 - $27.81 $14.4 Million - $32.2 Million	1,159,055 New	1,159,055 $17.2 Million

Others Institutions Holding RVNC

# of Institutions

196

Shares Held

81.5M

Call Options Held

490K

Put Options Held

128K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Revance Therapeutics, Inc. Transaction History